MedTrace Logo

Fertilix Supplements and Assisted Reproductive Technology

NCT02621125 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2017-05-02

No results posted yet for this study

Summary

This is a double blind, randomized, placebo controlled clinical trial to test the efficacy of the antioxidant formulation Fertilix® in lowering the levels of damaged sperm DNA in men diagnosed with moderate to high Sperm Oxidative DNA Damage (SODD)

Conditions

  • Spermatozoa

Interventions

DIETARY_SUPPLEMENT

Fertilix

daily supplementation

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • CellOxess LLC

    collaborator INDUSTRY

  • University Reproductive Associates

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02621125 on ClinicalTrials.gov